The Top 5 Biosimilars Articles for the Week of January 28

The Center for Biosimilars® recaps the top news for the week of January 28, 2019.


Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of January 28.

Number 5: The UK National Health Service has issued updated information on citrates in available biosimilar adalimumab.

Number 4: In observational studies of patients who have switched treatment from a reference biologic to a biosimilar, some higher rates of discontinuation may be related to the nocebo effect.

Number 3: During the CBI’s 14th Biosimilars Summit, the head of the FDA practice at Avalere said that enabling a global reference product for biosimilars would provide global access for patients.

Number 2: Bio-Thera Solutions announced that it has dosed the first patients in its phase 3 clinical study of BAT1806, a proposed biosimilar tocilizumab referencing Actemra.

Number 1: Coherus announced this week that it has become the latest biosimilar developer to settle with AbbVie, maker of brand-name adalimumab, Humira, over a proposed biosimilar. In an intellectual property twist, Coherus also announced that it has sued a rival biosimilar developer, Amgen.

Finally, last week, our e-newsletter asked if the confusion around the terms interchangeability, automatic substitution, and physician-mediated switching leads to reduced acceptance of biosimilars.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit

Related Videos
Michael Kleinrock
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Ian Henshaw
John Gabrielson
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumdschild, PharmD
Ryan Haumschild, PharmD
Ryan Haumschild, PharmD
Related Content
© 2023 MJH Life Sciences

All rights reserved.